WhiteFiber, Inc. (Nasdaq: WYFI) (“WhiteFiber” or the “Company”), a leading provider of AI infrastructure and HPC solutions, today announced its financial results for the third quarter ended September 30, 2025. https://mma.prnewswire.com/media/2745795/WhiteFiber_Logo.jpg Third Quarter 2025 Highlights — Total revenue of $20.2 million, up 65% year-over-year (from $12.3 million in 3Q 2024). — Cloud services revenue of […]
Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcast today at
— PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August — PAPZIMEOS launched with a broad label in the US as the first and only FDA-approved treatment for adults with RRP — PAPZIMEOS is now available and shipping to prescribers in the US for the treatment of adults with RRP — To date,
Biohaven Ltd.(NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closing of its underwritten public offering of 26,833,334 of its common shares, which includes the full exercise of the underwriters' option to purchase 3,500,000
Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter — Delivered $1.0 Million of Operating Income in Q3 2025 — Women's health innovator Evofem Biosciences, Inc.(Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2025 and provided a business update. https://mma.prnewswire.com/media/780907/Evofem_Biosciences_Logo.jpg
Reports 21% Increase in ARR to $21.3 Million, Strong Growth in Net Income, Adjusted EBITDA and Operating Cash Flow Research Solutions, Inc. (NASDAQ: RSSS), the leading AI-powered research workflow platform, reported financial results for its fiscal first quarter ended September 30, 2025. https://mma.prnewswire.com/media/2622870/RS_Logo.jpg Fiscal First Quarter 2026 Summary (compared to prior-year quarter) — Annual Recurring
Third QuarterRevenue was $320.9 Million Third Quarter Operating Loss was $(34.8) Million Third QuarterAdjusted OIBDA was $21.8 Million Total Revenue, OTT Revenue, and U.S. OTT Subscriber Growth U.S. OTT Subscriber Growth of 520,000 YTD and 670,000 YoY Engagement on STARZ App Reached 12-Month High During Period Management Reiterates All Previously Provided 2025 Outlook STARZ (NASDAQ:
(NASDAQ:XOS), Delivered 130 units and generated $16.5 million in revenue Achieved 15.3% Gross Margin and a second consecutive quarter of positive free cash flow Continued cost discipline with 24% year-over-year reduction in third quarter operating expenses LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leader in
(NASDAQ:JCAP), Collections Grow 63% to $236.8 Million and Deployments Grow 22% to $151.0 MillionPre-tax Income up 16% to $45.5 Million with Net Income of $38.4 Million and EPS of $0.59Adjusted Pre-tax Income up 30% to $54.8 Million with Adjusted Net Income of $47.7 Million and Adjusted EPS of $0.74Board of Directors Declares Quarterly Cash Dividend
(NASDAQ:GCTK), Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement